文献速递妇科

同源重组DNA修复缺陷的临床检测方法

Clinical assays for assessment of homologous recombination DNA repair deficiency.
PubMed 文献 · Gynecol Oncol · 2020-10-02

同源重组DNA修复缺陷(HRD)可由BRCA1/2等基因突变导致,对铂类和PARP抑制剂更敏感。基于基因组瘢痕的HRD检测(如Myriad基因组不稳定性评分、Foundation Medicine杂合性缺失检测)可用于预测PARP抑制剂获益,但不同检测方法在基因组特征和阈值定义上存在差异,且检测结果与PARP抑制剂反应可能不一致。

要点

  • HRD由BRCA1/2等基因突变或其他机制导致,对铂类和PARP抑制剂更敏感。
  • 基于基因组瘢痕的HRD检测可预测PARP抑制剂获益,但方法间异质性大。
  • HRD检测结果与PARP抑制剂反应可能不一致,需理解检测局限性。

核心结论

  • HRD检测是有前景的预测性生物标志物,可辅助卵巢癌患者选择PARP抑制剂和其他DNA损伤剂。

主要发现

  • BRCA1/2突变致HRD的患者比BRCA1/2野生型患者更可能对PARP抑制剂有反应。
  • 部分临床试验中,BRCA1/2野生型但经基因组检测预测为HRD的患者,PARP抑制剂临床获益大于无HRD证据的BRCA1/2野生型患者。
  • HRD检测结果与PARP抑制剂反应可不一致:回复突变恢复HR功能的肿瘤仍显示HRD基因组瘢痕,不依赖HR的PARP抑制剂耐药机制可导致HRD但无PARP抑制剂反应。

临床怎么用

  • 临床可应用HRD检测辅助筛选PARP抑制剂和其他DNA损伤剂的潜在获益患者。
  • 需理解不同HRD检测的基因组特征和阈值差异及其局限性,以确保最佳临床应用。

局限性

  • HRD检测在测量的基因组特征和定义HRD的阈值方法上存在差异。
  • HRD检测结果与PARP抑制剂反应可能不一致,存在回复突变和不依赖HR的耐药机制等问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Homologous recombination DNA repair deficiency (HRD) is a functional defect in homologous recombination DNA repair, arising from germline or somatic mutations in BRCA1/2 or other mechanisms. Cells with HRD are more sensitive to platinum and poly(ADP-ribose) polymerase inhibitors (PARPi). HRD generates permanent changes in the genome with specific, quantifiable patterns ("genomic scars"). Clinical tests for HRD, such as the Myriad genomic instability score and Foundation Medicine loss of heterozygosity test, aim to predict the presence of HRD based on genomic features. Clinical trials of PARPi in ovarian cancer have evaluated genetic mutations and HRD genomic assays as potential biomarkers of response. Patients with HRD due to BRCA1/2 mutations are more likely to respond to PARPi than those with wild-type (WT) BRCA1/2. In some clinical trials, patients with WT BRCA1/2 who were predicted to be HRD by a genomic test exhibited greater clinical benefit from PARPi than patients with WT BRCA1/2 and no evidence of HRD. HRD tests therefore hold promise as predictive biomarkers for PARPi and other DNA-damaging agents. However, HRD tests vary in terms of the specific genomic features they measure, and the methods used to determine thresholds defining patients with HRD. Also, HRD test results and PARPi responses can be discordant: for instance, tumors with reversion mutations that restore HR function still exhibit a "genomic scar" of HRD, and PARPi resistance mechanisms independent of HR can result in lack of PARPi response despite HRD. Emerging methods to predict HRD, including genomic and functional assays, may overcome some of these challenges. Evaluation of HRD in the clinical setting is an important tool that has potential to aid patient selection for PARPi and other DNA-damaging agents in ovarian cancer, but understanding the details of these tests and their limitations is critical to ensure their optimal clinical application.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Stover EH, Fuh K, Konstantinopoulos PA, et al. Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol. 2020. PMID: 33012552. doi:10.1016/j.ygyno.2020.09.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。